VMD-928 is under clinical development by VM Discovery and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VMD-928’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VMD-928 overview

VMD-928 is under development for the treatment of lymphoma, thymic carcinoma, thymoma, pancreatic cancer and mesothelioma, head and neck squamous cell carcinoma, ovarian cancer, hepatocellular carcinoma, squamous cell carcinoma of lung (squamous NSCLC), esophageal cancer, adenoid cystic carcinoma, prostate cancer, cervical cancer, gastric cancer, melanoma, acute myeloid leukemia, pancreatic carcinoma and non-Hodgkins' lymphoma. It is formulated as a capsule and administered through oral route. The drug candidate acts by targeting tropomyosin receptor kinase A (TrkA).

For a complete picture of VMD-928’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.